Jashvant Poeran1, Madhu Mazumdar2, Rehana Rasul2, Joanne Meyer3, Henry S Sacks4, Brian S Koll5, Frances R Wallach5, Alan Moskowitz6, Annetine C Gelijns6. 1. Department of Population Health Science and Policy, Institute for Healthcare Delivery Science, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: jashvant.poeran@mountsinai.org. 2. Department of Population Health Science and Policy, Institute for Healthcare Delivery Science, Icahn School of Medicine at Mount Sinai, New York, NY. 3. Department of Pharmacy, The Mount Sinai Hospital, New York, NY. 4. Icahn School of Medicine at Mount Sinai, New York, NY. 5. Icahn School of Medicine at Mount Sinai, New York, NY; Infection Prevention and Control, Mount Sinai Health System, New York, NY. 6. Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY.
Abstract
OBJECTIVE: Antibiotic use, particularly type and duration, is a crucial modifiable risk factor for Clostridium difficile. Cardiac surgery is of particular interest because prophylactic antibiotics are recommended for 48 hours or less (vs ≤24 hours for noncardiac surgery), with increasing vancomycin use. We aimed to study associations between antibiotic prophylaxis (duration/vancomycin use) and C difficile among patients undergoing coronary artery bypass grafting. METHODS: We extracted data on coronary artery bypass grafting procedures from the national Premier Perspective claims database (2006-2013, n = 154,200, 233 hospitals). Multilevel multivariable logistic regressions measured associations between (1) duration (<2 days, "standard" vs ≥2 days, "extended") and (2) type of antibiotic used ("cephalosporin," "cephalosporin + vancomycin," "vancomycin") and C difficile as outcome. RESULTS: Overall C difficile prevalence was 0.21% (n = 329). Most patients (59.7%) received a cephalosporin only; in 33.1% vancomycin was added, whereas 7.2% received vancomycin only. Extended prophylaxis was used in 20.9%. In adjusted analyses, extended prophylaxis (vs standard) was associated with significantly increased C difficile risk (odds ratio, 1.43; confidence interval, 1.07-1.92), whereas no significant associations existed for vancomycin use as adjuvant or primary prophylactic compared with the use of cephalosporins (odds ratio, 1.21; confidence interval, 0.92-1.60, and odds ratio, 1.39; confidence interval, 0.94-2.05, respectively). Substantial inter-hospital variation exists in the percentage of extended antibiotic prophylaxis (interquartile range, 2.5-35.7), use of adjuvant vancomycin (interquartile range, 4.2-61.1), and vancomycin alone (interquartile range, 2.3-10.4). CONCLUSIONS: Although extended use of antibiotic prophylaxis was associated with increased C difficile risk after coronary artery bypass grafting, vancomycin use was not. The observed hospital variation in antibiotic prophylaxis practices suggests great potential for efforts aimed at standardizing practices that subsequently could reduce C difficile risk.
OBJECTIVE: Antibiotic use, particularly type and duration, is a crucial modifiable risk factor for Clostridium difficile. Cardiac surgery is of particular interest because prophylactic antibiotics are recommended for 48 hours or less (vs ≤24 hours for noncardiac surgery), with increasing vancomycin use. We aimed to study associations between antibiotic prophylaxis (duration/vancomycin use) and C difficile among patients undergoing coronary artery bypass grafting. METHODS: We extracted data on coronary artery bypass grafting procedures from the national Premier Perspective claims database (2006-2013, n = 154,200, 233 hospitals). Multilevel multivariable logistic regressions measured associations between (1) duration (<2 days, "standard" vs ≥2 days, "extended") and (2) type of antibiotic used ("cephalosporin," "cephalosporin + vancomycin," "vancomycin") and C difficile as outcome. RESULTS: Overall C difficile prevalence was 0.21% (n = 329). Most patients (59.7%) received a cephalosporin only; in 33.1% vancomycin was added, whereas 7.2% received vancomycin only. Extended prophylaxis was used in 20.9%. In adjusted analyses, extended prophylaxis (vs standard) was associated with significantly increased C difficile risk (odds ratio, 1.43; confidence interval, 1.07-1.92), whereas no significant associations existed for vancomycin use as adjuvant or primary prophylactic compared with the use of cephalosporins (odds ratio, 1.21; confidence interval, 0.92-1.60, and odds ratio, 1.39; confidence interval, 0.94-2.05, respectively). Substantial inter-hospital variation exists in the percentage of extended antibiotic prophylaxis (interquartile range, 2.5-35.7), use of adjuvant vancomycin (interquartile range, 4.2-61.1), and vancomycin alone (interquartile range, 2.3-10.4). CONCLUSIONS: Although extended use of antibiotic prophylaxis was associated with increased C difficile risk after coronary artery bypass grafting, vancomycin use was not. The observed hospital variation in antibiotic prophylaxis practices suggests great potential for efforts aimed at standardizing practices that subsequently could reduce C difficile risk.
Authors: Andreas Beckmann; Klaus Doebler; Elke Schaefer; Joachim Koetting; Petra Gastmeier; Karolin Graf Journal: Eur J Cardiothorac Surg Date: 2011-01-31 Impact factor: 4.191
Authors: Annetine C Gelijns; Alan J Moskowitz; Michael A Acker; Michael Argenziano; Nancy L Geller; John D Puskas; Louis P Perrault; Peter K Smith; Irving L Kron; Robert E Michler; Marissa A Miller; Timothy J Gardner; Deborah D Ascheim; Gorav Ailawadi; Pamela Lackner; Lyn A Goldsmith; Sophie Robichaud; Rachel A Miller; Eric A Rose; T Bruce Ferguson; Keith A Horvath; Ellen G Moquete; Michael K Parides; Emilia Bagiella; Patrick T O'Gara; Eugene H Blackstone Journal: J Am Coll Cardiol Date: 2014-07-29 Impact factor: 24.094
Authors: Dale W Bratzler; E Patchen Dellinger; Keith M Olsen; Trish M Perl; Paul G Auwaerter; Maureen K Bolon; Douglas N Fish; Lena M Napolitano; Robert G Sawyer; Douglas Slain; James P Steinberg; Robert A Weinstein Journal: Surg Infect (Larchmt) Date: 2013-03-05 Impact factor: 2.150
Authors: Jonah J Stulberg; Conor P Delaney; Duncan V Neuhauser; David C Aron; Pingfu Fu; Siran M Koroukian Journal: JAMA Date: 2010-06-23 Impact factor: 56.272
Authors: Brian T Bateman; Jeremy A Rassen; Sebastian Schneeweiss; Katsiaryna Bykov; Jessica Myers Franklin; Joshua J Gagne; Jennifer M Polinski; Jun Liu; Alexander Kulik; Michael A Fischer; Niteesh K Choudhry Journal: J Thorac Cardiovasc Surg Date: 2013-03-28 Impact factor: 5.209
Authors: Erik R Dubberke; Kimberly A Reske; Yan Yan; Margaret A Olsen; L Clifford McDonald; Victoria J Fraser Journal: Clin Infect Dis Date: 2007-12-15 Impact factor: 9.079
Authors: David K Warren; Katelin B Nickel; Jennifer H Han; Pam Tolomeo; Christopher J Hostler; Katherine Foy; Ian R Banks; Victoria J Fraser; Margaret A Olsen Journal: Infect Control Hosp Epidemiol Date: 2020-05-05 Impact factor: 3.254
Authors: Katherine A Kirkwood; Brian C Gulack; Alexander Iribarne; Michael E Bowdish; Giampaolo Greco; Mary Lou Mayer; Karen O'Sullivan; Annetine C Gelijns; Nishit Fumakia; Ravi K Ghanta; Jesse M Raiten; Anuradha Lala; Joseph S Ladowski; Eugene H Blackstone; Michael K Parides; Alan J Moskowitz; Keith A Horvath Journal: J Thorac Cardiovasc Surg Date: 2017-09-28 Impact factor: 5.209
Authors: Margaret A Olsen; Katelin B Nickel; Victoria J Fraser; Anna E Wallace; David K Warren Journal: Infect Control Hosp Epidemiol Date: 2017-07-03 Impact factor: 3.254
Authors: Margaret A Olsen; Jacob K Greenberg; Kate Peacock; Katelin B Nickel; Victoria J Fraser; David K Warren Journal: J Antimicrob Chemother Date: 2022-03-31 Impact factor: 5.758